味之素起诉梅花生物及其子公司 索赔2.6亿元

Core Viewpoint - Meihua Biological has received a civil lawsuit from Ajinomoto Co., Inc. regarding patent infringement related to monosodium glutamate production and sales [2][4] Group 1: Legal Issues - Ajinomoto claims that Meihua Biological and its subsidiaries have infringed on two specific patents during the production and sales of monosodium glutamate [4] - The lawsuit demands that Meihua Biological and its subsidiaries cease all infringing activities, destroy equipment used for producing the infringing products, and compensate for economic losses totaling 260 million yuan [4] Group 2: Company Background - Meihua Biological has a long-standing partnership with Ajinomoto, with multiple collaborative agreements in the field of intellectual property and monosodium glutamate production technology [4] - As of the announcement date, the lawsuit has not yet been publicly heard, and the company has indicated uncertainty regarding the potential impact on its financial performance [4] Group 3: Financial Performance - For the first three quarters, Meihua Biological reported a revenue of 18.215 billion yuan, a year-on-year decrease of 2.49%, and a net profit of 3.025 billion yuan, a year-on-year increase of 51.61% [4] - In the third quarter alone, the company achieved a revenue of 5.935 billion yuan, a year-on-year decrease of 1.71%, while net profit surged to 1.257 billion yuan, reflecting a year-on-year increase of 141.06% [4]